Tafamidis

Tafamidis
Clinical data
Trade names	Vyndaqel, Vyndamax, others
AHFS/Drugs.com	Monograph
License data	US DailyMed: Tafamidis;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	N07XX08 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 2-(3,5-Dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid;
CAS Number	594839-88-0 ;
PubChem CID	11001318;
DrugBank	DB11644 ;
ChemSpider	9176510 ;
UNII	8FG9H9D31J;
KEGG	D09673;
ChEBI	CHEBI:78538 ;
ChEMBL	ChEMBL2103837;
CompTox Dashboard (EPA)	DTXSID00208185 ;
ECHA InfoCard	100.246.079
Chemical and physical data
Formula	C14H7Cl2NO3
Molar mass	308.11 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)c3ccc1nc(oc1c3)-c2cc(Cl)cc(Cl)c2;
	InChI InChI=1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H,(H,18,19) ; Key:TXEIIPDJKFWEEC-UHFFFAOYSA-N ;
	(what is this?) (verify)

Tafamidis, sold under the brand names Vyndaqel and Vyndamax,^[5] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy, as well as wild-type transthyretin amyloidosis, which formerly was called senile systemic amyloidosis. It works by stabilizing the quaternary structure of the protein transthyretin. In people with transthyretin amyloidosis, transthyretin falls apart and forms clumps called (amyloid) that harm tissues including nerves and the heart.^[6]^[7]

The US Food and Drug Administration considers tafamidis to be a first-in-class medication.^[8]

^ ^a ^b "Vyndamax and Vyndaqel Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 17 July 2020. Retrieved 16 August 2020.
^ "Summary Basis of Decision (SBD) for Vyndaqel". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
^ Cite error: The named reference UKlabel was invoked but never defined (see the help page).
^ ^a ^b Cite error: The named reference Vyndaqel and Vyndamax label was invoked but never defined (see the help page).
^ ^a ^b Cite error: The named reference Vyndaqel EPAR was invoked but never defined (see the help page).
^ Cite error: The named reference FDA PR was invoked but never defined (see the help page).
^ "New Drug Therapy Approvals 2019". U.S. Food and Drug Administration. 31 December 2019. Archived from the original on 2 May 2020. Retrieved 15 September 2020.

[Vyndamax_and_Vyndaqel_APMDS-1] "Vyndamax and Vyndaqel Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 17 July 2020. Retrieved 16 August 2020.

[2] "Summary Basis of Decision (SBD) for Vyndaqel". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[3] "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.

[UKlabel-4] Cite error: The named reference UKlabel was invoked but never defined (see the help page).

[Vyndaqel_and_Vyndamax_label-5] Cite error: The named reference Vyndaqel and Vyndamax label was invoked but never defined (see the help page).

[Vyndaqel_EPAR-6] Cite error: The named reference Vyndaqel EPAR was invoked but never defined (see the help page).

[FDA_PR-7] Cite error: The named reference FDA PR was invoked but never defined (see the help page).

[8] "New Drug Therapy Approvals 2019". U.S. Food and Drug Administration. 31 December 2019. Archived from the original on 2 May 2020. Retrieved 15 September 2020.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]